Dividendos de Inhibrx

Dividendo controles de criterios 0/6

Inhibrx no tiene antecedentes de pago de dividendos.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.9%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$5.09
Rentabilidad por dividendo prevista a 3 años	0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Oct 03

Inhibrx: Potential To Move To Registration Study With INBRX-101

Jun 10

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23

Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results

May 16

What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?

Jan 14

Inhibrx's INBRX-109 wins FDA's Fast Track status

Jan 13

Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors

Jan 05

Need To Know: Analysts Are Much More Bullish On Inhibrx, Inc. (NASDAQ:INBX) Revenues

Nov 22

Inhibrx EPS misses by $0.07

Nov 13

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de INBX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de INBX han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Inhibrx vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de INBX con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (INBX)	n/a
Suelo de mercado 25% (US)	1.6%
Techo de mercado 25% (US)	4.8%
Media de la industria (Biotechs)	2.9%
Previsión de analistas en 3 años (INBX)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de INBX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de INBX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de INBX para determinar si sus dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que INBX no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dividendos de Inhibrx

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Executive VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Price target decreased by 20% to US$35.50

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

Consensus revenue estimates increase by 26%

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 85%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Consensus revenue estimates increase by 42%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

Inhibrx: Potential To Move To Registration Study With INBRX-101

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Consensus revenue estimates fall by 17%

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Price target decreased to US$49.67

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased to US$49.67

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020)

Price target increased to US$42.60

Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020)

Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study

Consensus forecasts updated

Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results

First quarter 2021 earnings released: US$0.51 loss per share (vs US$1.05 loss in 1Q 2020)

Consensus forecasts updated

Inhibrx, Inc. Announces Results from the Single Agent Dose Escalation of the Phase 1 Study of INBRX-105

Full year 2020 earnings released: US$3.01 loss per share (vs US$2.83 loss in FY 2019)

Revenue and earnings beat expectations

New 90-day low: US$22.17

Inhibrx, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to INBRX-109

What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?

Inhibrx's INBRX-109 wins FDA's Fast Track status

Inhibrx, Inc. Announces Results from Part 1 of the Phase 1 Dose Escalation Trial of Inbrx-106

Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors

Arecor's Partner Inhibrx Exercises Its Option to License A New Formulation Developed by Arecor

New 90-day high: US$37.42

Need To Know: Analysts Are Much More Bullish On Inhibrx, Inc. (NASDAQ:INBX) Revenues